Oklo general counsel sells $27,056 in company stock

Vivek Narayanadas, General Counsel and Secretary at Oklo Inc. (NYSE:OKLO), sold 1,021 shares of the company’s Class A Common Stock on October 20, 2026, for a total value of $27,056. The shares were sold at a price of $26.5 per share.

The transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Narayanadas on April 2, 2026. Following this sale, Mr. Narayanadas directly owns 10,669 shares of Oklo Inc. Class A Common Stock.The sale comes as Oklo shares trade near their 52-week low of $26.31, with the stock down 78% over the past year. According to InvestingPro analysis, which offers 17 additional exclusive tips for OKLO, the company’s financial health rating stands at "weak" despite holding more cash than debt on its balance sheet.

Separately, the reported beneficial ownership was adjusted to correct an administrative double-counting of 4,120 shares in prior reports. These shares were initially included in the reporting person’s opening direct holdings and subsequently included again when related restricted stock units settled. No transaction occurred in connection with this correction.

In other recent news, Oklo Inc. has seen several updates from analysts regarding its stock ratings and price targets. Piper Sandler lowered its price target on Oklo shares to $49 from $55, citing increased capital expenditure estimates for new plants. Despite this adjustment, the firm maintains an Overweight rating on the stock. Meanwhile, Canaccord Genuity reiterated a Buy rating with a $100 price target, noting that revenue from Oklo’s isotope division may remain modest but could exceed expectations as the Groves-2 project progresses.

Additionally, Piper Sandler reaffirmed its confidence in Oklo’s capabilities following a visit to the Groves facility, maintaining an Overweight rating and a $55 price target. Truist Securities continues to hold a Hold rating with a $51 price target, highlighting ongoing development activities across Oklo’s business segments. UBS, on the other hand, reduced its price target to $41 from $55, citing updated estimates that include a slight increase in expected expenses and a decrease in long-term R&D spending projections. These developments reflect varied perspectives on Oklo’s financial outlook and strategic projects.